Provided by Tiger Trade Technology Pte. Ltd.

SINO BIOPHARM

6.390
-0.450-6.58%
Volume:91.28M
Turnover:591.60M
Market Cap:119.88B
PE:29.36
High:6.810
Open:6.810
Low:6.390
Close:6.840
52wk High:9.120
52wk Low:3.107
Shares:18.76B
HK Float Shares:18.76B
Volume Ratio:3.51
T/O Rate:0.49%
Dividend:0.09
Dividend Rate:1.48%
EPS(LYR):0.218
ROE:15.40%
ROA:5.07%
PB:3.16
PE(LYR):29.36
PS:3.45

Loading ...

Sino Biopharmaceutical Stock Slides 6.6% in Hong Kong, Underperforms Competitors

Dow Jones
·
1 hour ago

Sino Biopharmaceutical Stock Rises 1.8% in Hong Kong

Dow Jones
·
Feb 20

BRIEF-Sino Biopharmaceutical Says NMPA Approved Benmelstobart Injection For Marketing

Reuters
·
Feb 16

Sino Biopharm (1177) Announces Approval of Benmelstobart Injection for NSCLC Maintenance Therapy

Bulletin Express
·
Feb 16

SINO BIOPHARM's Innovative Drug Bemusubain Injection Gains Approval for New NSCLC Indication

Stock News
·
Feb 16

Sino Biopharmaceutical - Approval for Marketing of Benmelstobart Injection by China's Nmpa

THOMSON REUTERS
·
Feb 16

Sino Biopharmaceutical Gains NMPA Approval for Benmelstobart in Stage III NSCLC Maintenance Therapy

Reuters
·
Feb 16

Sino Biopharmaceutical Stock Slips 0.9% in Hong Kong, Underperforms Competitors

Dow Jones
·
Feb 13

Sino Biopharmaceutical Stock Sheds 3.7% in Hong Kong, Underperforms Competitors

Dow Jones
·
Feb 12

Bank of America Securities Reaffirms Buy Rating on Sino Biopharm Following Positive Progress on Two Drug Candidates

Stock News
·
Feb 12

Small Nucleic Acids Reshape Weight Loss Paradigm with INHBE and ALK7 Targets Showing Initial Validation

Stock News
·
Feb 12

Stock Track | SINO BIOPHARM Soars 5.00% Intraday on Completion of Phase III Trial Enrollment for Breast Cancer Drug

Stock Track
·
Feb 10

Sino Biopharmaceutical Completes Subject Enrollment in Phase 3 Trial of Breast Cancer Drug

MT Newswires Live
·
Feb 10

Chinese Pharmaceutical Firm Completes Patient Enrollment for Phase III Trial of HER2-Targeting Drug

Stock News
·
Feb 10

Sino Biopharm (1177) Completes Phase III Enrollment for TQB2102 “HER2 Bispecific ADC” in HER2-Low Breast Cancer

Bulletin Express
·
Feb 10

Sino Biopharm Completes Enrollment for Phase III Trial of HER2 Bispecific ADC in HER2-Low Breast Cancer

Reuters
·
Feb 10

Sino Biopharmaceutical Stock Rallies 1.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Feb 09

BUZZ-Sino Biopharm climbs most in five weeks on cancer drug development progress

Reuters
·
Feb 09

SINO BIOPHARM (01177): Patient Enrollment Completed for Phase III Trial of Claudiximab "CLDN18.2 ADC"

Stock News
·
Feb 09

Sino Biopharmaceutical (1177) Announces Completion of Phase III Enrollment for Tecotabart Vedotin “CLDN18.2 ADC”

Bulletin Express
·
Feb 09